Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study

• Joseph F Merola,
• Frank Behrens,
• Marina Magrey,
• Liang Chen,
• Derek Haaland,
• Koji Kato,
• Mitsumasa Kishimoto,
• Patrick Zueger,
• Aileen L Pangan,
• Cesar Pacheco-Tena,
• John Liu,
• Yuanyuan Duan,
• Ralph Lippe

Affiliations

Joseph F Merola

Department of Rheumatology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA

Frank Behrens

3 CIRI/Rheumatology and Fraunhofer TMP, Goethe-University, Frankfurt, Germany

Marina Magrey

School of Medicine at Metrohealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA

Liang Chen

Department of Immunology, AbbVie Inc, North Chicago, Illinois, USA

Derek Haaland

Department of Medicine, McMaster University, Hamilton, Ontario, Canada

Koji Kato

Department of Immunology, AbbVie Inc, North Chicago, Illinois, USA

Mitsumasa Kishimoto

Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan

Patrick Zueger

Department of Immunology, AbbVie Inc, North Chicago, Illinois, USA

Aileen L Pangan

Department of Immunology, AbbVie Inc, North Chicago, Illinois, USA

Cesar Pacheco-Tena

Facultad de Medicina, Universidad Autónoma de Chihuahua, Chihuahua, Mexico

John Liu

Department of Immunology, AbbVie Inc, North Chicago, Illinois, USA

Yuanyuan Duan

Department of Immunology, AbbVie Inc, North Chicago, Illinois, USA

Ralph Lippe

Department of Immunology, AbbVie Deutschland GmbH & Co KG, Wiesbaden, Hesse, Germany